The FDA warns that all patient should take the first dose of brand-name Amiodarone or generic form pacerone after being admitted to the hospital to ensure the safety of their well-being and the drug’s efficacy. The nursing staff and doctor will likely need to monitor the patient while in the hospital to ensure they receive the correct dosage. Known specific side effects include: In December 1985, amiodarone was approved by the FDA for the treatment of arrhythmias. This makes amiodarone one of the few drugs approved by the FDA without rigorous randomized clinical trials. Amiodarone hydrochloride tablets are indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. Read about amiodarone (Cordarone, Nextrone, Pacerone), a drug used for many serious arrhythmias of the heart including ventricular fibrillation, ventricular tachycardia, atrial fibrillation, and atrial flutter. Side effects, drug interactions, dosing and storage information, and pregnancy information is included. Amiodarone (Cordarone) is a complex antiarrhythmic agent with multiple electrophysiologic effects, unusual pharmacokinetics, and numerous potentially harmful drug interactions and adverse effects. In December 1985, amiodarone was approved by the FDA for the treatment of arrhythmias. This makes amiodarone one of the few drugs approved by the FDA without rigorous randomized clinical trials. [citation needed] Name. Cordarone ® (amiodarone HCl) TABLETS. Rx only. DESCRIPTION. Cordarone (amiodarone HCl) is a member of a class of antiarrhythmic drugs with predominantly Class III (Vaughan Williams’ classification) effects, available for oral Amiodarone affects the rhythm of your heartbeats. It is used to help keep the heart beating normally in people with life-threatening heart rhythm disorders of the ventricles (the lower chambers of the heart that allow blood to flow out of the heart). FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in. Original New Drug Approvals (NDAs and BLAs) by Month All applications approved for the first time during the selected month. Includes New Molecular Entities (NMEs) and new biologics.